Search

Zai Lab Ltd ADR

Закрыт

СекторЗдравоохранение

26.86 6.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

25.33

Макс.

28.49

Ключевые показатели

By Trading Economics

Доход

191K

-51M

Продажи

6.7M

106M

Прибыль на акцию

-0.46

Рентабельность продаж

-47.808

Сотрудники

1,784

EBITDA

-2.1M

-46M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+54.37% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

637M

2.7B

Предыдущая цена открытия

20.82

Предыдущая цена закрытия

26.86

Zai Lab Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 нояб. 2026 г., 23:51 UTC

News

Jefferies maintains a Buy rating on Airbnb, Inc. and raises its price target to $230, citing confidence in the company's growth prospects.

9 нояб. 2026 г., 23:51 UTC

News

EVI Industries reports Q1 earnings of $0.24 per share, exceeding estimates, with revenue of $112.948 million and a 108% increase in net income to $3.847 million.

9 нояб. 2026 г., 23:51 UTC

News
Event

Mesa Laboratories reports Q2 net income of $4.34 million, revenue of $62.34 million, and projects full-year revenue of $250M to $255M.

9 нояб. 2026 г., 23:41 UTC

News

Steady as U.S. wholesale inventories rose in September.

9 нояб. 2026 г., 23:26 UTC

News

U.S. Nuclear Regulatory Commission grants Dow Inc. a construction permit for four Xe-100 small modular reactors at its UCC Seadrift Operations site in Texas.

9 нояб. 2026 г., 23:21 UTC

News

Under Armour's price declines in after-market trading after Telsey Advisory Group lowered its price target to $5 while maintaining a Market Perform rating.

9 нояб. 2026 г., 23:21 UTC

News

Amazon.com Inc announced that OpenAI's ChatGPT Enterprise is now available through AWS Marketplace, enhancing its position in the AI market.

9 нояб. 2026 г., 23:21 UTC

News

Telsey Advisory Group maintained a Market Perform rating on Under Armour Inc and lowered its price target to $5 in a report published after the market closed.

9 нояб. 2026 г., 23:16 UTC

Correlated Moves
News

Moody's upgraded SM Energy Co's corporate family rating to Ba2 from Ba3, citing significant balance-sheet improvement and reduced debt of $6.8 billion.

9 нояб. 2026 г., 23:16 UTC

News

Steel Dynamics announces a $3.0 billion share repurchase program and declares a quarterly cash dividend of $0.53 per share, payable January 8, 2027.

9 нояб. 2026 г., 23:16 UTC

News

Teradyne, Inc. announced a quarterly cash dividend of $0.13 per share, payable on December 16, 2026, to shareholders on record as of November 23, 2026.

9 нояб. 2026 г., 23:16 UTC

News

Coherus Oncology reports Q3 2026 revenue of $14.3M, up from $11.6M year-over-year, and announces a strategic plan with a 30% workforce reduction.

9 нояб. 2026 г., 23:12 UTC

News

Apollo Global Management, Inc. has priced a $600 million offering of 7.550% Fixed-Rate Resettable Junior Subordinated Notes due 2056, closing on November 13, 2026.

9 нояб. 2026 г., 23:11 UTC

Social Media
News

NVIDIA's stock price advanced after former President Trump expressed confidence in CEO Jensen Huang amid an FBI investigation into allegations involving a suspected Chinese spy.

9 нояб. 2026 г., 23:11 UTC

News

Jefferies maintains Hold rating on Duolingo, Inc. while raising price target to $175, reflecting the firm's assessment of the company's market position and growth potential.

9 нояб. 2026 г., 23:11 UTC

News

Orrstown Financial Services announces a strategic repositioning of its AFS securities portfolio, involving a $185.6 million sale and a $13.8 million pre-tax loss.

9 нояб. 2026 г., 23:06 UTC

News

Grab Holdings Limited reported third-quarter revenue above estimates and record adjusted EBITDA, but the stock is trading modestly lower in after-market hours.

9 нояб. 2026 г., 23:06 UTC

News

Constellation Energy Corp shares are trading modestly lower in after-market hours, following a notable decline after the market closed.

9 нояб. 2026 г., 23:06 UTC

News

Syndax Pharmaceuticals grants CFO Aaron A. Ondrey an inducement award for 270k shares at an exercise price vesting over four years, approved by the Board.

9 нояб. 2026 г., 23:06 UTC

News

Northrop Grumman Corp will not contest its loss of the $20B F/A-XX Navy fighter program to Boeing, with shares trading flat in after-market hours.

9 нояб. 2026 г., 23:02 UTC

News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million loss, with operating expenses rising to $120.1 million.

9 нояб. 2026 г., 23:02 UTC

News

FutureFuel Corp reported a net loss of $8.4 million for Q3, despite a revenue increase to $104.7 million driven by strong biodiesel demand.

9 нояб. 2026 г., 23:02 UTC

Social Media
News

AbCellera Biologics reports Q3 2026 revenue of $10.63 million, surpassing estimates, and a net loss of $40.8 million, improved from last year.

9 нояб. 2026 г., 23:02 UTC

Social Media
News

Harrow, Inc. reported record Q3 revenue of $99.3 million and GAAP net income of $9.8 million, a turnaround from a loss last quarter.

9 нояб. 2026 г., 23:02 UTC

Social Media
News

Hims & Hers Health, Inc. reported a Q3 net loss of $33 million and lowered its Q4 revenue outlook, missing analyst expectations.

9 нояб. 2026 г., 23:02 UTC

News

Paysign Inc reported Q3 earnings with EPS of $0.11 and revenue of $30.8 million, raising full-year 2026 GAAP EPS guidance to $0.37-$0.38.

9 нояб. 2026 г., 23:02 UTC

News

First Advantage Corporation launches a secondary offering of 15 million shares by Silver Lake Group, with no proceeds going to the company.

9 нояб. 2026 г., 23:02 UTC

News
Social Media

Plug Power Inc. reported Q3 2026 revenue of approximately $201 million, a 13% increase, and a GAAP EPS of $0.07, improving from a loss of $0.31.

9 нояб. 2026 г., 23:02 UTC

News

Cantor Fitzgerald initiates coverage on DICK'S Sporting Goods with a Neutral rating and a price target of $146.00.

9 нояб. 2026 г., 23:02 UTC

News
Social Media

AAON, Inc. reported record third-quarter net sales of $707.4 million, exceeding expectations, and raised its full-year revenue growth outlook to 72%-75%.

Сравнение c конкурентами

Изменение цены

Zai Lab Ltd ADR Прогноз

Целевая цена

By TipRanks

54.37% рост

Прогноз на 12 месяцев

Средняя 39.333 USD  54.37%

Максимум 45 USD

Минимум 36 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Zai Lab Ltd ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

3

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat